Yisheng Bio and US Army Institute to Collaborate on Ebola Vaccine

Yisheng Biopharma, a Beijing vaccine company, will collaborate with the United States Army Medical Research Institute of Infectious Diseases to develop an Ebola vaccine using Yisheng's proprietary PKA adjuvant. The agreement was signed between the USAMRIID and Yishing's US subsidiary. Apparently, both entities will have rights to vaccines developed by the collaboration, for either Ebola or other viruses. More details.... Share this with colleagues: // //  
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.